A Phase I and Pharmacological Study with Imidazolium-<b> <i>trans-</i> </b>DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent

2004820 citationsJournal Articlegreen Open Access

Authors

NAMI-A can be administered safely as a 3-h i.v. infusion at a dose of 300 mg/m(2)/day for 5 days, every 3 weeks.

Good health and well-being

Published in: Clinical Cancer Research

Volume 10, Issue 11, pp. 3717-3727

Field-Weighted Citation Impact: 11.62